These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2880981)

  • 21. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
    Palmieri B; Gasparini Casari M; DiBlasio P; Zirilli E
    Arzneimittelforschung; 1981; 31(10a):1863-6. PubMed ID: 7032534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fatty acid metabolism in hepatocytes cultured with hypolipidaemic drugs. Role of carnitine.
    Gerondaes P; Alberti KG; Agius L
    Biochem J; 1988 Jul; 253(1):161-7. PubMed ID: 3048253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of etofibrate on the development and the regression of atheromas in a rabbit model of atherosclerosis.
    Betz E; Quack G
    Vasa; 1990; 19(2):157-60. PubMed ID: 2371790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypolipemic activity of plafibride.
    Bruseghini L; Vilageliu J; Bagaria A
    Arzneimittelforschung; 1981; 31(10a):1796-800. PubMed ID: 7198456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Etofibrate lowers the atherosclerosis index].
    Mertz DP; Suermann I; Göhmann E
    Med Klin; 1981 Mar; 76(6):166-8. PubMed ID: 7231329
    [No Abstract]   [Full Text] [Related]  

  • 26. Activity of plafibride on erythrocyte deformability.
    Vilageliu J; Freixes J; Bruseghini L
    Arzneimittelforschung; 1983; 33(3):401-4. PubMed ID: 6683514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The analysis of [14C]clofibric acid glucuronide and [14C]clofibric acid in plasma and urine using high-performance liquid chromatography.
    Meffin PJ; Zilm DM
    J Chromatogr; 1983 Nov; 278(1):101-8. PubMed ID: 6662867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Species differences in the hepatic response to a potent peroxisome proliferator.
    Makowska JM; Bonner FW; Goldfarb PS; Gibson GG
    Biochem Soc Trans; 1989 Dec; 17(6):1072-3. PubMed ID: 2628085
    [No Abstract]   [Full Text] [Related]  

  • 29. [Etofibrate in severe diet-refractory cases of hyperlipoproteinemia].
    Schatton W; Holm E
    Fortschr Med; 1986 Apr; 104(13):280-2. PubMed ID: 3699655
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of ciprofibrate and 2-[5-(4-chlorophenyl)pentyl]oxirane-2-carboxylate (POCA) on the distribution of carnitine and CoA and their acyl-esters and on enzyme activities in rats. Relation between hepatic carnitine concentration and carnitine acetyltransferase activity.
    Bhuiyan AK; Bartlett K; Sherratt HS; Agius L
    Biochem J; 1988 Jul; 253(2):337-43. PubMed ID: 3178716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia.
    Dick TB; Marples J; Ledermann HM; Whittington J
    Curr Med Res Opin; 1981; 7(8):489-502. PubMed ID: 7030635
    [No Abstract]   [Full Text] [Related]  

  • 32. [The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia].
    Gajdos M; Fedelesova V; Mongiellova V; Cibulova L; Huttova D; Polak F; Krivosikova Z
    Bratisl Lek Listy; 1999 Aug; 100(8):449-53. PubMed ID: 10645034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The short- and long-term effects of bezafibrate in the rat.
    Fahimi HD; Reinicke A; Sujatta M; Yokota S; Ozel M; Hartig F; Stegmeier K
    Ann N Y Acad Sci; 1982; 386():111-35. PubMed ID: 6953842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Single-blind study of the efficacy of pirozadil versus alufibrate in the treatment of primary hyperlipoproteinemias].
    Honorato Pérez J; Azanza Perea JR
    Rev Med Univ Navarra; 1982 Mar; 26(1):51-4. PubMed ID: 7111953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic approach of plafibride in rat.
    Zapatero D; Vilageliu J; Torres A; Ribalta JM; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1800-4. PubMed ID: 7198457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enantiomers of clofibric acid analogs have opposite actions on rat skeletal muscle chloride channels.
    Conte-Camerino D; Mambrini M; DeLuca A; Tricarico D; Bryant SH; Tortorella V; Bettoni G
    Pflugers Arch; 1988 Nov; 413(1):105-7. PubMed ID: 2464159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective increase in acylation of 1-acylglycerophosphorylcholine in livers of rats and mice by peroxisome proliferators.
    Kawashima Y; Hirose A; Kozuka H
    Biochim Biophys Acta; 1984 Apr; 793(2):232-7. PubMed ID: 6712968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Species differences in the metabolic conjugation of clofibric acid and clofibrate in laboratory animals and man.
    Emudianughe TS; Caldwell J; Sinclair KA; Smith RL
    Drug Metab Dispos; 1983; 11(2):97-102. PubMed ID: 6133730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of hypolipidaemic drugs to acyl-coenzyme A thioesters.
    Bronfman M; Amigo L; Morales MN
    Biochem J; 1986 Nov; 239(3):781-4. PubMed ID: 3827829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plafibride tolerance trial in healthy volunteers.
    Dalmau J; Vicens B; Zapatero J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1845-9. PubMed ID: 7198463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.